Bribery risks in clinical trial approvals

Introduction

Bribery risks in clinical trial approvals refer to the possibility of offering, giving, receiving or demanding unlawful benefits to influence regulatory decisions concerning the approval, supervision or conduct of clinical trials. Such practices undermine the independence of regulatory authorities, compromise scientific integrity and may expose research participants to unsafe or inadequately tested medicines.

Clinical trials are essential for evaluating the safety and effectiveness of new drugs, vaccines, biological products and medical technologies. Before a clinical trial can begin, sponsors and investigators must satisfy applicable legal, scientific and ethical requirements. Regulatory authorities and Institutional Ethics Committees (IECs) play an important role in evaluating research protocols, informed consent procedures, participant safety and scientific justification.

Bribery may occur when pharmaceutical companies, clinical research organisations (CROs), investigators or intermediaries attempt to influence these approval processes through financial payments, gifts, hospitality, employment benefits or other improper advantages.

In India, bribery in clinical trial approvals may attract liability under anti-corruption legislation, pharmaceutical regulations, criminal law and corporate governance requirements.

Legal framework governing bribery in clinical trial approvals in India

1. Prevention of Corruption Act, 1988

The Prevention of Corruption Act, 1988, as amended in 2018, is the principal Indian legislation dealing with corruption involving public servants.

Important provisions include:

Section 7 – Public servant being bribed

Section 7 criminalises a public servant's acceptance or attempt to obtain an undue advantage in connection with the improper or dishonest performance of public duties.

For example, if a public regulatory official demands money from a pharmaceutical company in exchange for approving a clinical trial without proper scrutiny, the conduct may attract Section 7.

Section 7A – Taking undue advantage to influence a public servant

This provision addresses situations where a person accepts or attempts to obtain an undue advantage to induce a public servant to perform public duties improperly.

An intermediary who demands payment from a clinical trial sponsor by claiming that the money will secure favourable regulatory treatment may attract this provision, depending on the facts.

Section 8 – Bribing a public servant

Section 8 criminalises the giving or promising of an undue advantage to induce a public servant to perform public duties improperly. The statutory protection for a person compelled to give a bribe is subject to the conditions prescribed by the provision, including reporting within the specified period.

Section 9 – Bribing by commercial organisations

A commercial organisation may be liable where a person associated with it gives or promises an undue advantage to a public servant to obtain or retain business or an advantage in the conduct of business.

This provision is particularly relevant to pharmaceutical companies and clinical research organisations seeking regulatory approvals.

Section 10 – Liability of persons in charge of commercial organisations

Persons in charge of a commercial organisation may face liability where the organisation commits an offence under Section 9 and the statutory conditions are satisfied. The provision also recognises a defence where the person establishes that the offence occurred without their knowledge or that they exercised due diligence to prevent it.

2. New Drugs and Clinical Trials Rules, 2019

The New Drugs and Clinical Trials Rules, 2019, issued under the Drugs and Cosmetics Act, 1940, establish the regulatory framework for clinical trials involving new drugs and investigational new drugs in India.

The Rules address:

Permission requirements for conducting clinical trials.

Responsibilities of sponsors and investigators.

Registration and functioning of Ethics Committees.

Informed consent and participant protection.

Compensation for trial-related injury or death.

Regulatory supervision and reporting obligations.

Clinical trial approval must be based on scientific and ethical assessment rather than private payments or personal influence.

3. Drugs and Cosmetics Act, 1940

The Drugs and Cosmetics Act, 1940 provides the broader regulatory framework for the import, manufacture, distribution and sale of drugs in India.

The Central Drugs Standard Control Organisation (CDSCO), headed by the Drugs Controller General of India (DCGI), performs important regulatory functions relating to new drugs and clinical trials.

Corrupt interference with these functions can undermine the statutory system designed to protect public health.

4. Bharatiya Nyaya Sanhita, 2023

The Bharatiya Nyaya Sanhita, 2023, which came into force on 1 July 2024, contains provisions dealing with offences such as cheating, criminal breach of trust, forgery and falsification-related conduct.

Depending on the facts, fraudulent clinical trial documentation, fabricated approvals or diversion of research funds may attract relevant criminal provisions in addition to anti-corruption legislation.

Major bribery risks in clinical trial approvals

1. Bribery of regulatory officials

One major risk arises when pharmaceutical companies or their representatives offer money or other benefits to regulatory officials to obtain faster or favourable approval.

Such conduct may result in approval of trials without adequate scientific assessment, participant protection or regulatory scrutiny.

2. Improper payments to Ethics Committee members

Institutional Ethics Committees independently evaluate clinical trial protocols and monitor participant welfare.

Bribery risks may arise where sponsors offer financial benefits, expensive gifts or personal advantages to committee members in exchange for favourable opinions.

This compromises the independence of ethical review and may permit unsafe or poorly designed studies to proceed.

3. Payments to investigators and research institutions

Clinical investigators and research institutions may face conflicts of interest when they receive undisclosed financial benefits from sponsors.

Payments that are not properly disclosed or are linked to favourable trial outcomes may undermine research independence.

However, legitimate investigator fees and institutional research payments are not automatically bribes. They must be transparent, contractually documented and consistent with applicable ethical and regulatory requirements.

4. Manipulation of clinical trial documents

Bribery may be associated with false documentation, including:

Fabricated ethical approval records.

False participant consent forms.

Manipulated safety reports.

Incorrect declarations of investigator qualifications.

Concealed financial conflicts of interest.

Falsified regulatory correspondence.

Such conduct may result in regulatory action and criminal liability, depending on the circumstances.

5. Conflict of interest in clinical research

A conflict of interest occurs when personal or financial interests interfere, or appear to interfere, with professional judgment.

For example, an investigator who receives undisclosed financial benefits from a pharmaceutical sponsor may face pressure to report favourable results or overlook adverse events.

Institutions should require disclosure of financial relationships and independent review of potential conflicts.

Regulatory safeguards against bribery

Effective prevention requires a combination of legal controls, institutional independence and internal corporate governance.

1. Independent Ethics Committees

Ethics Committees should evaluate trial protocols independently and document their decisions. Members should disclose financial and professional conflicts of interest.

2. Transparent approval procedures

Regulatory decisions should be supported by documented scientific assessments, written reasons where required and traceable official records.

3. Financial disclosure

Sponsors, investigators and research institutions should maintain accurate records of payments, research grants, consultancy fees and other financial relationships.

4. Internal compliance programmes

Pharmaceutical companies should establish anti-bribery policies, employee training, approval procedures for third-party payments and confidential reporting mechanisms.

5. Independent audits

Internal and external audits can identify suspicious transactions, unexplained consultancy fees, irregular payments and discrepancies in clinical trial records.

6. Whistle-blower mechanisms

Employees, investigators and research participants should have appropriate channels to report suspected corruption without fear of retaliation.

Important case laws

There are limited reported Indian judgments directly addressing bribery in clinical trial approvals. However, the following cases establish important legal principles concerning corruption, regulatory accountability, medical ethics and clinical research.

1. Vineet Narain v. Union of India (1998)

The Supreme Court considered the investigation of corruption allegations involving public officials and emphasised the need for institutional independence and effective enforcement of anti-corruption laws.

The judgment led to important directions concerning the functioning and independence of investigative agencies.

Relevance: Clinical trial approvals involve regulatory decision-making that must remain independent of political, commercial or personal influence. The principles in this case support transparent investigations into allegations of corruption involving regulatory officials.

2. Subramanian Swamy v. Manmohan Singh (2012)

The Supreme Court examined the issue of granting sanction for prosecution of public servants accused of corruption.

The Court emphasised that decisions concerning prosecution sanction should be made within a reasonable time and that unnecessary delays can weaken anti-corruption enforcement.

Relevance: Where public officials are suspected of accepting bribes to influence clinical trial approvals, timely investigation and prosecution are important to maintaining regulatory accountability.

3. Centre for Public Interest Litigation v. Union of India (2011)

Commonly known as the 2G spectrum allocation case, the Supreme Court examined irregularities in the allocation of public resources and emphasised fairness, transparency and the rule of law in governmental decision-making.

Relevance: Although the case did not involve clinical trials, its principles apply to regulatory approval systems. Clinical trial permissions should be granted through fair, objective and transparent procedures rather than personal influence or improper financial benefits.

4. Jacob Mathew v. State of Punjab (2005)

The Supreme Court examined the standards applicable to criminal liability for medical negligence and emphasised the importance of establishing the required level of negligence before imposing criminal responsibility on medical professionals.

Relevance: Clinical trial investigators and medical professionals must comply with professional and ethical responsibilities. However, ordinary negligence and bribery are distinct legal issues. The case is relevant to the broader accountability of medical professionals rather than being a direct bribery precedent.

5. Samira Kohli v. Dr. Prabha Manchanda (2008)

The Supreme Court examined the requirements of informed consent in medical treatment and emphasised that consent must be voluntary and based on adequate information.

Relevance: Bribery or improper financial influence in clinical trial approvals can undermine participant protection. Ethical oversight must ensure that research participants receive appropriate information and provide genuine informed consent.

6. State of Maharashtra v. Dnyaneshwar Laxman Rao Wankhede (2009)

The Supreme Court considered the legal requirements for establishing an offence under the Prevention of Corruption Act, including the significance of proving the relevant elements of the alleged demand and acceptance of illegal gratification.

Relevance: Allegations that regulatory officials accepted bribes for clinical trial approvals must be supported by legally admissible evidence and proof of the statutory elements of the offence. Suspicion or irregular procedure alone does not automatically establish bribery.

International anti-bribery standards

International standards also influence the governance of multinational pharmaceutical companies and clinical research organisations.

1. OECD Anti-Bribery Convention, 1997

The Convention requires participating countries to criminalise bribery of foreign public officials in international business transactions. It is relevant to pharmaceutical companies seeking approvals in foreign jurisdictions.

2. United States Foreign Corrupt Practices Act, 1977

The FCPA prohibits specified bribery of foreign officials and imposes accounting and internal-control requirements on covered entities.

It may become relevant where a company or transaction falls within its jurisdictional scope.

3. UK Bribery Act, 2010

The UK Bribery Act criminalises bribery and includes an offence concerning failure by commercial organisations to prevent bribery by associated persons, subject to a defence based on adequate procedures.

It provides an important compliance model for multinational clinical research organisations.

4. International Council for Harmonisation – Good Clinical Practice (ICH-GCP)

ICH Good Clinical Practice principles promote ethical and scientific quality in clinical trials. They require appropriate responsibilities, documentation, monitoring and protection of trial participants.

Although GCP is not itself a general anti-bribery statute, its requirements support transparent and accountable clinical research.

Challenges in preventing bribery

Complex approval procedures: Multiple regulatory and institutional review stages may create opportunities for improper influence.

Third-party intermediaries: Consultants and agents may conceal unlawful payments through misleading service agreements.

Financial conflicts: Undisclosed payments to investigators or committee members can compromise independence.

Weak monitoring: Inadequate audits may allow irregular transactions to remain undetected.

Cross-border transactions: Multinational sponsors may face different anti-corruption laws and enforcement standards.

Fear of retaliation: Employees may hesitate to report suspected bribery where whistle-blower protection is ineffective.

Conclusion

Bribery risks in clinical trial approvals threaten scientific integrity, regulatory independence and the safety of research participants. In India, the Prevention of Corruption Act, 1988, Drugs and Cosmetics Act, 1940, and New Drugs and Clinical Trials Rules, 2019 provide important legal safeguards against corruption and improper influence in clinical research.

Judicial decisions such as Vineet Narain, Subramanian Swamy and Centre for Public Interest Litigation reinforce the importance of transparency, accountability and independent regulatory decision-making. Although these judgments do not directly concern bribery in clinical trial approvals, their principles are relevant to the governance of regulatory institutions.

An effective prevention framework requires independent Ethics Committees, transparent approval procedures, financial disclosures, internal audits, whistle-blower protection and strict enforcement of anti-corruption laws. These safeguards help ensure that clinical trial approvals are based on scientific evidence, ethical standards and public health considerations rather than financial influence.